Kazia Therapeutics EBITDA
Cos'è EBITDA di Kazia Therapeutics?
EBITDA di Kazia Therapeutics Limited è -AUD$22.91
Qual è la definizione di EBITDA?
L'EBITDA è il reddito di una società prima di interessi, imposte, deprezzamenti e ammortamenti ed è una misura contabile calcolata utilizzando gli utili netti di una società, prima che vengano sottratti interessi passivi, imposte, ammortamenti e ammortamenti come proxy della redditività corrente di un'azienda.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA di aziende nel Health Care settore su ASX rispetto a Kazia Therapeutics
Cosa fa Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Aziende con ebitda simili a Kazia Therapeutics
- Vtex ha EBITDA di -$23.21
- Puxin ha EBITDA di -¥23.19
- Corvus Gold ha EBITDA di -CAD$23.08
- Corvus Gold ha EBITDA di -CAD$23.08
- Hempfusion Wellness ha EBITDA di -$23.06
- Clenergen ha EBITDA di -$22.99
- Kazia Therapeutics ha EBITDA di -AUD$22.91
- Shield Therapeutics Plc ha EBITDA di -£22.90
- China Shun Ke Long ha EBITDA di -¥22.90
- Sezzle ha EBITDA di -$22.90
- Sezzle ha EBITDA di -$22.90
- GreenBox POS ha EBITDA di -$22.87
- Navya SA ha EBITDA di -€22.86